Skip to Main Content

When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave — it represented the “overall value this treatment brings to patients, caregivers and society” — came right out of Mick Kolassa’s playbook.

For many years, Kolassa was the man drug companies turned to when they wanted advice on how to price a drug.


While Biogen earlier this year had to take the unusual step of cutting the price of a new medication, halving the cost of Aduhelm in the U.S. market, there has been only one direction of travel for drug prices — up.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.